Baxter International (BAX)
Baxter International on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on NYSE, classified by the SEC as surgical & medical instruments & apparatus.
24.4M
Short interest
settlement 2026-09-30
3.0
Days to cover
-1.5 days vs prior
65.9%
Short share of volume
2026-10-09
2,111
Fails to deliver
settlement 2026-09-09
Thu 29 Oct
Next earnings
estimated date
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-10-09.
Short interest
FINRA, twice a month. The newest 24 settlements in the table, 48 in the chart. JSONAs of 30 September 2026, short interest in BAX is 24,366,869 shares, up 1,073,202 shares over the last month. Over the last 48 readings it ranged from 11,471,367 shares (31 October 2024) to 42,637,728 shares (13 February 2026). At the reported average volume of 8.2M shares a day that is 3.0 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/bax" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-09-30 | 24,366,869 | +4.9% | 8,190,013 | 2.98 |
| 2026-09-15 | 23,227,313 | -0.3% | 5,185,542 | 4.48 |
| 2026-08-31 | 23,293,667 | -2.6% | 4,667,401 | 4.99 |
| 2026-08-14 | 23,914,369 | -26.8% | 7,950,123 | 3.01 |
| 2026-07-31 | 32,667,256 | -11.3% | 7,531,769 | 4.34 |
| 2026-07-15 | 36,839,907 | -4.5% | 5,647,222 | 6.52 |
| 2026-06-30 | 38,589,003 | -7.4% | 7,059,803 | 5.47 |
| 2026-06-15 | 41,665,129 | -1.8% | 6,942,537 | 6.00 |
| 2026-05-29 | 42,412,694 | +5.1% | 6,894,441 | 6.15 |
| 2026-05-15 | 40,350,973 | +15.0% | 7,208,384 | 5.60 |
| 2026-04-30 | 35,078,391 | -6.5% | 8,800,027 | 3.99 |
| 2026-04-15 | 37,529,498 | -6.9% | 6,329,674 | 5.93 |
| 2026-03-31 | 40,311,678 | +6.9% | 9,603,920 | 4.20 |
| 2026-03-13 | 37,706,710 | -1.7% | 10,041,477 | 3.76 |
| 2026-02-27 | 38,375,340 | -10.0% | 11,478,312 | 3.34 |
| 2026-02-13 | 42,637,728 | +19.8% | 12,378,134 | 3.44 |
| 2026-01-30 | 35,589,146 | +5.4% | 7,768,704 | 4.58 |
| 2026-01-15 | 33,761,661 | -1.1% | 10,117,118 | 3.34 |
| 2025-12-31 | 34,151,713 | +2.0% | 6,969,693 | 4.90 |
| 2025-12-15 | 33,496,034 | +1.1% | 8,795,750 | 3.81 |
| 2025-11-28 | 33,142,899 | +13.0% | 7,626,319 | 4.35 |
| 2025-11-14 | 29,331,326 | +15.5% | 10,182,691 | 2.88 |
| 2025-10-31 | 25,397,908 | -3.9% | 7,504,518 | 3.38 |
| 2025-10-15 | 26,421,428 | -3.0% | 5,421,399 | 4.87 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 9 October 2026, the short share of BAX volume is 65.9%, up 13.6 points over the last five sessions. Over the last 30 readings it ranged from 34.6% (23 September 2026) to 73.0% (9 September 2026). The latest reading is 14.3 points above the 30-session average of 51.6%, on 921K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-10-09 | 607K | 921K | 65.9% | 339 |
| 2026-10-08 | 712K | 1.4M | 50.7% | 675 |
| 2026-10-07 | 1.0M | 1.7M | 60.3% | 1,357 |
| 2026-10-06 | 1.2M | 2.6M | 48.2% | 825 |
| 2026-10-05 | 1.9M | 4.5M | 42.6% | 414 |
| 2026-10-02 | 740K | 1.4M | 52.3% | 17,657 |
| 2026-10-01 | 1.1M | 2.0M | 54.6% | 39 |
| 2026-09-30 | 1.8M | 3.0M | 62.1% | 78 |
| 2026-09-29 | 1.2M | 2.6M | 47.1% | 0 |
| 2026-09-28 | 1.1M | 1.7M | 66.2% | 1,435 |
| 2026-09-25 | 924K | 1.9M | 47.6% | 2,135 |
| 2026-09-24 | 1.2M | 2.7M | 42.0% | 3,124 |
| 2026-09-23 | 1.5M | 4.4M | 34.6% | 517 |
| 2026-09-22 | 1.2M | 2.6M | 45.3% | 3,535 |
| 2026-09-21 | 1.7M | 4.9M | 35.4% | 103 |
| 2026-09-18 | 1.1M | 1.8M | 62.5% | 943 |
| 2026-09-17 | 1.4M | 2.4M | 56.4% | 201 |
| 2026-09-16 | 1.8M | 4.0M | 44.9% | 27,189 |
| 2026-09-15 | 1.4M | 2.4M | 59.0% | 484 |
| 2026-09-14 | 729K | 2.0M | 37.2% | 2,030 |
| 2026-09-11 | 1.1M | 2.3M | 50.0% | 185 |
| 2026-09-10 | 870K | 1.9M | 44.7% | 1,532 |
| 2026-09-09 | 1.2M | 1.7M | 73.0% | 1,461 |
| 2026-09-08 | 1.1M | 2.1M | 53.3% | 2,095 |
| 2026-09-04 | 692K | 1.2M | 59.8% | 432 |
| 2026-09-03 | 902K | 1.6M | 55.5% | 713 |
| 2026-09-02 | 828K | 1.6M | 53.3% | 42 |
| 2026-09-01 | 1.1M | 2.0M | 55.9% | 1,680 |
| 2026-08-31 | 544K | 1.1M | 47.7% | 75 |
| 2026-08-28 | 628K | 1.6M | 40.4% | 2,629 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 9 September 2026, the fails-to-deliver balance in BAX is 2,111 shares, up 2,029 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (21 July 2026) to 332,200 shares (9 June 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-09 | 2,111 | $24.86 | $52K |
| 2026-09-02 | 82 | $25.48 | $2K |
| 2026-08-24 | 43,037 | $26.34 | $1.1M |
| 2026-08-21 | 49,054 | $26.41 | $1.3M |
| 2026-08-18 | 98 | $25.91 | $3K |
| 2026-08-07 | 578 | $27.01 | $16K |
| 2026-08-05 | 33,278 | $28.35 | $943K |
| 2026-08-04 | 4,559 | $28.10 | $128K |
| 2026-08-03 | 101,400 | $26.16 | $2.7M |
| 2026-07-31 | 1,877 | $26.75 | $50K |
| 2026-07-30 | 870 | $24.77 | $22K |
| 2026-07-22 | 710 | $22.21 | $16K |
| 2026-07-21 | 1 | $22.07 | $22 |
| 2026-07-20 | 2,478 | $22.61 | $56K |
| 2026-07-17 | 2 | $23.35 | $47 |
| 2026-07-16 | 300 | $22.15 | $7K |
| 2026-07-10 | 1,665 | $22.46 | $37K |
| 2026-07-02 | 1,000 | $21.69 | $22K |
| 2026-06-30 | 18 | $22.02 | $396 |
| 2026-06-29 | 79,607 | $22.04 | $1.8M |
| 2026-06-26 | 45 | $21.55 | $970 |
| 2026-06-25 | 433 | $21.04 | $9K |
| 2026-06-23 | 470 | $19.66 | $9K |
| 2026-06-22 | 3,673 | $19.89 | $73K |
| 2026-06-18 | 67,888 | $19.39 | $1.3M |
| 2026-06-16 | 2,422 | $20.81 | $50K |
| 2026-06-15 | 5,435 | $20.86 | $113K |
| 2026-06-12 | 137 | $20.49 | $3K |
| 2026-06-11 | 28,751 | $20.31 | $584K |
| 2026-06-09 | 332,200 | $19.24 | $6.4M |
Insider trades
SEC Form 4, newest first, 50 of 100 shown. JSONNo open-market insider trades were reported for BAX in the last 90 days. The most recent filings are listed below. Latest filing: Hider Andrew P. (President and CEO) on 2026-09-02.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-09-02 | Hider Andrew P. | President and CEO | Tax withholding | 54K | $25.70 | $1.4M | 518K |
| 2026-09-02 | Foster Julie | President, Front Line Care | Tax withholding | 2K | $25.70 | $54K | 29K |
| 2026-09-01 | Teaff James | President, CCS | Tax withholding | 750 | $25.48 | $19K | 30K |
| 2026-06-02 | Wallace Steven P. | President, Adv. Surgery | Tax withholding | 153 | $18.68 | $3K | 70K |
| 2026-06-02 | Teaff James | President, CCS | Tax withholding | 321 | $18.68 | $6K | 31K |
| 2026-06-01 | Zielinski Anita A | SVP, Interim CFO, CAO & Cntrlr | Grant | 13K | $0.00 | $0 | 60K |
| 2026-05-05 | Wilkes David S. | Director | Grant | 13K | $0.00 | $0 | 37K |
| 2026-05-05 | Wendell Amy McBride | Director | Grant | 13K | $0.00 | $0 | 44K |
| 2026-05-05 | SCHLICHTING NANCY M | Director | Grant | 13K | $0.00 | $0 | 35K |
| 2026-05-05 | MORRISON PATRICIA | Director | Grant | 13K | $0.00 | $0 | 42K |
| 2026-05-05 | Shafer David Brent | Director, Chair of the Board | Grant | 13K | $0.00 | $0 | 73K |
| 2026-05-05 | McDonnell Michael R. | Director | Grant | 13K | $0.00 | $0 | 15K |
| 2026-05-05 | Craig Jeffrey A | Director | Grant | 13K | $0.00 | $0 | 24K |
| 2026-05-05 | Ampofo William A. II | Director | Grant | 13K | $0.00 | $0 | 30K |
| 2026-03-06 | Zielinski Anita A | SVP, CAO and Controller | Tax withholding | 2K | $17.69 | $34K | 46K |
| 2026-03-06 | Soriano Maria Cecilia | Group Pres., ITT & Pharma. | Tax withholding | 3K | $17.69 | $50K | 75K |
| 2026-03-06 | Rosenbloom David S. | EVP and General Counsel | Tax withholding | 7K | $17.69 | $117K | 138K |
| 2026-03-06 | Rasul Reazur | EVP,Group Pres,Healthcare | Tax withholding | 13K | $17.69 | $224K | 126K |
| 2026-03-06 | Grade Joel T. | EVP and CFO | Tax withholding | 8K | $17.69 | $144K | 272K |
| 2026-03-02 | Rasul Reazur | EVP,Group Pres,Healthcare | Tax withholding | 2K | $19.69 | $32K | 138K |
| 2026-03-02 | Soriano Maria Cecilia | Group Pres., ITT & Pharma. | Tax withholding | 2K | $19.69 | $36K | 78K |
| 2026-03-02 | Rosenbloom David S. | EVP and General Counsel | Tax withholding | 1K | $19.69 | $26K | 145K |
| 2026-02-27 | Hider Andrew P. | President and CEO | Grant | 202K | $0.00 | $0 | 572K |
| 2026-02-27 | Carlisle Cynthia | Executive Vice President, CHRO | Grant | 12K | $0.00 | $0 | 30K |
| 2026-02-27 | Carlisle Cynthia | Executive Vice President, CHRO | Grant | 18K | $0.00 | $0 | 18K |
| 2026-02-27 | Soriano Maria Cecilia | Group Pres., ITT & Pharma. | Grant | 24K | $0.00 | $0 | 80K |
| 2026-02-27 | Rosenbloom David S. | EVP and General Counsel | Grant | 27K | $0.00 | $0 | 146K |
| 2026-02-27 | Grade Joel T. | EVP and CFO | Grant | 43K | $0.00 | $0 | 280K |
| 2026-02-27 | Zielinski Anita A | SVP, CAO and Controller | Grant | 31K | $0.00 | $0 | 48K |
| 2026-02-13 | McDonnell Michael R. | Director | Grant | 2K | $0.00 | $0 | 2K |
| 2026-02-09 | Soriano Maria Cecilia | Group Pres., ITT & Pharma. | Tax withholding | 918 | $21.73 | $20K | 56K |
| 2026-02-09 | Soriano Maria Cecilia | Group Pres., ITT & Pharma. | Grant | 2K | $0.00 | $0 | 57K |
| 2026-02-09 | Rosenbloom David S. | EVP and General Counsel | Tax withholding | 5K | $21.73 | $114K | 119K |
| 2026-02-09 | Rosenbloom David S. | EVP and General Counsel | Grant | 17K | $0.00 | $0 | 125K |
| 2026-02-09 | Rasul Reazur | EVP,Group Pres,Healthcare | Tax withholding | 6K | $21.73 | $125K | 140K |
| 2026-02-09 | Rasul Reazur | EVP,Group Pres,Healthcare | Grant | 19K | $0.00 | $0 | 146K |
| 2026-02-09 | Grade Joel T. | EVP and CFO | Tax withholding | 9K | $21.73 | $199K | 237K |
| 2026-02-09 | Grade Joel T. | EVP and CFO | Grant | 31K | $0.00 | $0 | 246K |
| 2025-12-12 | Mason Jeanne K | EVP, Chief HR Officer | Tax withholding | 650 | $19.15 | $12K | 200K |
| 2025-12-01 | Grade Joel T. | EVP and CFO | Tax withholding | 8K | $19.08 | $158K | 215K |
| 2025-09-02 | Sonig Alok | EVP,Group President,Pharma | Tax withholding | 3K | $24.17 | $77K | 128K |
| 2025-09-02 | Hider Andrew P. | President and CEO | Grant | 132K | $0.00 | $0 | 368K |
| 2025-09-02 | Hider Andrew P. | President and CEO | Grant | 236K | $0.00 | $0 | 236K |
| 2025-09-02 | Grade Joel T. | EVP and CFO | Grant | 103K | $0.00 | $0 | 223K |
| 2025-09-02 | Borzi James W | EVP,Chief Supply Chain Officer | Tax withholding | 2K | $24.17 | $45K | 72K |
| 2025-08-19 | Shafer David Brent | Director, Chair of the Board | Tax withholding | 31K | $24.33 | $762K | 59K |
| 2025-06-02 | Rosenbloom David S. | EVP and General Counsel | Tax withholding | 17K | $29.55 | $489K | 106K |
| 2025-05-06 | Craig Jeffrey A | Director | Grant | 7K | $0.00 | $0 | 11K |
| 2025-05-06 | Ampofo William A. II | Director | Grant | 7K | $0.00 | $0 | 17K |
| 2025-05-06 | MORRISON PATRICIA | Director | Grant | 7K | $0.00 | $0 | 29K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON1 Form 144 notice on file for BAX worth $645K at the prices reported; 0 in the last 90 days worth $0. Latest: STEPHEN N. OESTERLE REV TRUST filed on 2026-05-18 to sell 36,347 shares ($645K) from 2026-05-18.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-05-18 | STEPHEN N. OESTERLE REV TRUSTFormer Affiliate | 36K | $645K | 0.007% | 2026-05-18 | Morgan Stanley Smith Barney LLC Executive Financial Services |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON7 holders report 5% or more of BAX in their latest filing, all on Schedule 13G (passive). The largest reported stake is PZENA INVESTMENT MANAGEMENT LLC at 12.7% of the class (65,347,621 shares), filed 2026-04-21 for an event on 2026-03-31.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-06-05 | 13G/Ano. 2 | Abigail P. Johnsonindividual | 53.0M | 10.3% | 2026-05-29 |
| 2026-06-05 | 13G/Ano. 2 | FMR LLCparent holding company | 53.0M | 10.3% | 2026-05-29 |
| 2026-04-29 | 13G | Vanguard Capital Managementinvestment adviser | 38.0M | 7.4% | 2026-03-31 |
| 2026-04-27 | 13G/Ano. 12 | BlackRock, Inc.parent holding company | 33.1M | 6.4% | 2026-03-31 |
| 2026-04-21 | 13G/Ano. 4 | PZENA INVESTMENT MANAGEMENT LLCinvestment adviser | 65.3M | 12.7% | 2026-03-31 |
| 2026-03-26 | 13G/Ano. 11 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
| 2026-01-21 | 13G/Ano. 2 | BlackRock Portfolio Management LLCparent holding company | 44.9M | 8.7% | 2025-12-31 |
| 2025-11-13 | 13G/Ano. 4 | Dodge & Coxinvestment adviser | 57.4M | 11.2% | 2025-09-30 |
13F holders
Tracked managers holding BAX at their latest 13F. JSON5 of the 30 tracked managers held BAX at their latest 13F, $46.9M in total at quarter-end prices. AQR Capital Management is the largest at $41.3M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 3 added shares and 2 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| AQR Capital Management | 2026-06-30 | 1.9M | $41.3M | 0.01% | +1.4M |
| Citadel Advisors | 2026-06-30 | 223K | $4.7M | 0.00% | -1.1M |
| Bridgewater Associates | 2026-06-30 | 17K | $370K | 0.00% | +1K |
| D. E. Shaw & Co. | 2026-06-30 | 16K | $338K | 0.00% | +5K |
| Millennium Management | 2026-06-30 | 10K | $215K | 0.00% | -1.7M |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 FY 2026 (quarter ended 2026-06-30) Baxter International reported revenue of $2.96B, up 5.3% from the same quarter a year earlier, and net income of $126.0M (0.24 diluted EPS). In FY 2025 it generated $845.0M of operating cash flow and spent $348.0M on dividends.
- Cash
- $2.15B
- Equity
- $6.21B
- Total assets
- $19.79B
- Shares outstanding
- 516,995,999
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | $2.96B | $126.0M | 4.3% | 0.24 |
| Q1 FY 2026 | 2026-03-31 | $2.70B | -$15.0M | -0.6% | -0.03 |
| Q4 FY 2025derived | 2025-12-31 | $2.97B | -$1.13B | -37.9% | n/a |
| Q3 FY 2025 | 2025-09-30 | $2.83B | -$46.0M | -1.6% | -0.09 |
| Q2 FY 2025 | 2025-06-30 | $2.81B | $91.0M | 3.2% | 0.18 |
| Q1 FY 2025 | 2025-03-31 | $2.63B | $126.0M | 4.8% | 0.25 |
| Q4 FY 2024 | 2024-12-31 | $2.75B | -$512.0M | -18.6% | -1.00 |
| Q3 FY 2024 | 2024-09-30 | $2.70B | $140.0M | 5.2% | 0.27 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $11.24B | -$957.0M | $845.0M | $513.0M | n/a | $348.0M |
| FY 2024 | 2024-12-31 | $10.64B | -$649.0M | $1.02B | $446.0M | $0 | $590.0M |
| FY 2023 | 2023-12-31 | $10.36B | $2.66B | $1.73B | $432.0M | $0 | $586.0M |
| FY 2022 | 2022-12-31 | $10.06B | -$2.43B | $1.21B | $377.0M | $32.0M | $573.0M |
| FY 2021 | 2021-12-31 | $12.15B | $1.28B | $2.22B | $691.0M | $600.0M | $530.0M |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-23 from the cover page.
What this page is
Baxter International in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Baxter International (BAX), SEC CIK 10456, listed on NYSE, classified by the SEC as surgical & medical instruments & apparatus. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-09-30.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-10-09.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-09.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-05-18.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-06-05.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-07-30.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-09-02.JSON and CSV
- Company record
- EDGAR filing index for CIK 10456Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as surgical & medical instruments & apparatus
- BSXBoston Scientific
- TNDMTandem Diabetes Care
- DXCMDexCom
- PENPenumbra
- INSPInspire Medical Systems
- SIBNSi-Bone
- LMATLemaitre Vascular
- MMM3M
- NVCRNovoCure
- RMDResMed
- SYKStryker
- GKOSGlaukos
- IRTCiRhythm Holdings
- ICUIIcu Medical
- ATECAlphatec Holdings
- IARTIntegra Lifesciences Holdings
- AORTArtivion
- PODDInsulet
- BDXBecton, Dickinson
- IRMDIradimed
- SIShoulder Innovations
- ATRCAtriCure
- CERSCerus
- TMCITreace Medical Concepts
Datasets
Frequently Asked Questions
How much of BAX is sold short?
What is BAX's daily short volume?
Does BAX have fails to deliver?
Are BAX insiders buying or selling?
Have BAX insiders filed to sell?
Who owns 5% or more of BAX?
What did BAX report last quarter?
Which tracked 13F managers own BAX?
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.